Mainz Biomed N.V. (MYNZ) Stock Price, Quote & News

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 49 6131 554 2860

Website: mainzbiomed.com

Address:

Robert Koch Strasse 50, Mainz, Germany

Duskfall Oct. 23 at 5:10 PM

$MYNZ 👍

0 · Reply

Manwiththeplan Oct. 21 at 3:13 PM

$MYNZ how will this company solve its financial situation?

3 · Reply

BlueSquirrel7 Oct. 21 at 10:43 AM

$MYNZ What do you think about competition with Galleri tests for detecting about 50 types of cancer from Grail?

0 · Reply

BlueSquirrel7 Oct. 20 at 5:58 AM

$MYNZ What would be the next catalysts for MYNZ? Thank you!

1 · Reply

twixbarrtwits Oct. 18 at 5:29 PM

$MYNZ

1 · Reply

andreatorchio1970 Oct. 17 at 7:23 PM

$MYNZ gooooo

0 · Reply

Genesys01 Oct. 16 at 9:28 PM

$MYNZ A very interesting German company which nobody has on the radar until now. Could be a mistake, because this is NOT an Israeli Scam.

2 · Reply

Tbio64 Oct. 15 at 1:26 PM

$MYNZ news out...

1 · Reply

Tbio64 Oct. 15 at 1:26 PM

$MYNZ news

0 · Reply

Duncan_ Oct. 14 at 7:26 PM

$MYNZ Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. Each year, about 466,000 lives are taken globally, and it’s the seventh leading cause of cancer-related death worldwide.1 It has one of the lowest survival rates of any cancer, with typically late detection and poor outcomes with standard of care treatment(s). The 5-year overall survival rate is approximately 11% in the U.S.2 and 9% globally.3 However, if diagnosis occurs in the early stages of the disease, the survival rate is significantly higher.

0 · Reply

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Sep 2, 2025, 8:01 AM EDT - 7 weeks ago

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Aug 13, 2025, 8:01 AM EDT - 2 months ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 4, 2025, 10:22 AM EDT - 2 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Jul 23, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 15, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jun 25, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 10, 2025, 9:01 AM EDT - 4 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

May 19, 2025, 8:01 PM EDT - 5 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025, 8:01 AM EDT - 5 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 29, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 28, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025, 9:01 AM EDT - 7 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 3, 2025, 8:01 AM EST - 8 months ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Feb 20, 2025, 8:01 AM EST - 8 months ago

Mainz Biomed Expands into Switzerland with labor team w

Feb 11, 2025, 8:01 AM EST - 9 months ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Jan 27, 2025, 8:01 AM EST - 9 months ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 21, 2025, 8:01 AM EST - 9 months ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024, 8:01 AM EST - 11 months ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 11 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 11 months ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 11 months ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 11 months ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 22, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 21, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Dec 19, 2023, 3:39 PM EST - 2 years ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Duskfall Oct. 23 at 5:10 PM

$MYNZ 👍

0 · Reply

Manwiththeplan Oct. 21 at 3:13 PM

$MYNZ how will this company solve its financial situation?

3 · Reply

BlueSquirrel7 Oct. 21 at 10:43 AM

$MYNZ What do you think about competition with Galleri tests for detecting about 50 types of cancer from Grail?

0 · Reply

BlueSquirrel7 Oct. 20 at 5:58 AM

$MYNZ What would be the next catalysts for MYNZ? Thank you!

1 · Reply

twixbarrtwits Oct. 18 at 5:29 PM

$MYNZ

1 · Reply

andreatorchio1970 Oct. 17 at 7:23 PM

$MYNZ gooooo

0 · Reply

Genesys01 Oct. 16 at 9:28 PM

$MYNZ A very interesting German company which nobody has on the radar until now. Could be a mistake, because this is NOT an Israeli Scam.

2 · Reply

Tbio64 Oct. 15 at 1:26 PM

$MYNZ news out...

1 · Reply

Tbio64 Oct. 15 at 1:26 PM

$MYNZ news

0 · Reply

Duncan_ Oct. 14 at 7:26 PM

0 · Reply

Duncan_ Oct. 14 at 7:26 PM

$MYNZ “We are excited about the collaboration with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection. A first-in-class screening test for pancreatic cancer would be a major achievement in the fight of this devastating disease,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Liquid Biosciences is already a key partner for our next generation colorectal cancer screening test. Expanding our partnership will allow us to leverage the power of AI also for the detection of this deadly form of cancer.”

1 · Reply

Duncan_ Oct. 14 at 7:25 PM

$MYNZ cont. The recently completed first phase of the collaboration included the evaluation of biomarkers from the Company’s research program co-funded by the German Federal Ministry for Education and Research, and applied a single algorithm developed by Liquid Biosciences using its EMERGE platform. The results of this feasibility analysis were promising, leading the Company and Liquid Biosciences to believe that a PancAlert diagnostic test could, in the future, be combined with Mainz Biomed’s colorectal cancer screening product. The Company and Liquid Biosciences plan to continue with the second phase of the collaboration, for which the evaluation of biomarkers will be expanded to include the microbiome biomarkers that were analyzed in collaboration with Microba Life Sciences in 2023, as well as an extension of the AI algorithm. The companies plan to complete this analysis in the fourth quarter of 2024.

0 · Reply

Duncan_ Oct. 14 at 7:24 PM

$MYNZ Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert article : link https://finance.yahoo.com/news/mainz-biomed-partners-liquid-biosciences-080100831.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACKnpS-Lcr-3EF8lJgtNUDY2qr7ZOTjAO3p5lnUgX5gEQcmZTHFzpgDz4UrMo9bjEI6qm4FtGkRkdNie_wYi_z5EMh7Kb2dELFyQxj1nswqpRvwMZB74stshuxMlsF0E3QGKmEuTQmtVi0iOgT-G5LyAb794cYaN20UBhgs2Bgbw PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection test for pancreatic cancer. The companies will leverage Liquid Biosciences proprietary AI analysis technology platform (EMERGE) to expand and optimize the selection of novel biomarkers for PancAlert.

0 · Reply

Bogdanoff2142 Oct. 14 at 2:12 PM

$CING decent volume for the first half hour. NDA acceptance and soon patent news, first adhd drug that is active a whole day with a single pill. $MYNZ $SPRB $IXHL $DRUG

1 · Reply

SMARTR8 Oct. 14 at 2:04 PM

$MYNZ Stop missing out 🤫

0 · Reply

SMARTR8 Oct. 14 at 1:49 PM

$MYNZ bought starter at 1.50 ✅️🤝

0 · Reply

Xochi_Resaerch_Group Oct. 13 at 8:50 PM

$MYNZ obviously back down lol

0 · Reply

ridgecrest123 Oct. 12 at 12:14 AM

$MYNZ As a physician this seems like a game changer. Pancreatic cancer is usually detected when a cure is no longer possible. It has one of the highest mortality rates of any cancer. The ColoAlert is an appetizer and certainly valuable but offering a possible early diagnosis of pancreatic cancer with a simple blood test is not only financially rewarding as an investor, but potentially will save thousands if not millions of lives

1 · Reply

Orlandotrader Oct. 10 at 6:34 PM

$MYNZ The study used a set of 18 biomarkers owned by Liquid Biosciences to test a patient's blood for pancreatic cancer. The test achieved 100% sensitivity, identifying every person with pancreatic cancer, and 95% specificity, identifying most people without the cancer. Great Results folks. Hand in this Company will Eventually get Recognition. When it does to the Moon Alice. Market cap will climb rapidly and the company will be able to Raise Real Money to Develop Cholo Alert and The Pancreatic Test Kit.

1 · Reply

benzinga Oct. 10 at 4:52 PM

Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland $MYNZ https://www.benzinga.com/partner/biotech/25/10/48145433/mainz-biomed-update-early-detection-test-for-pancreatic-cancer-demonstrates-never-before-seen-res

0 · Reply

_CircuitBreaker Oct. 9 at 11:18 PM

Keep a close watch on CMCT! $MYNZ $UA $AGMH $MNST 1

0 · Reply

ASTS11 Oct. 9 at 4:02 PM

$BURU $MYNZ Mainz Biomed (NASDAQ:MYNZ) reported topline feasibility results for a non-invasive, blood-based pancreatic cancer screening test using 18 licensed biomarkers. In a 30-subject cohort the leading panel achieved 100% sensitivity and 95% specificity, and the algorithm also detected precancerous lesions. These results align with earlier discovery/validation datasets that showed 95% sensitivity and 98% specificity. Mainz Biomed will plan a larger confirmatory study using banked retrospective samples, then a PCR-based validation study and potential future FDA submission, pending outcomes.

0 · Reply

Market Cap	8.61M
Revenue (ttm)	890,000.00
Net Income (ttm)	-21.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,432.58%
Debt to Equity Ratio	0.19

Volume	124,000
Avg Vol	254,130
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	71%
Beta	0.25
Analysts	Strong Sell
Price Target	$14.00